case_images: PMC6689764_01
case_images: Bone turnover marker (TRAP-5b, total-P1NP) levels. TRAP-5b and total-P1NP levels increased immediately following discontinuation of denosumab.. Abbreviations: Dmab, Denosumab; TRAP-5b, tartrate-resistant acid phosphatase type 5; total-P1NP, total N-terminal propeptide of type I procollagen.
case_images: CIA-14-1445-g0001.jpg
case_images: PMC6689764_01_CIA-14-1445-g0001.jpg
case_images: F0001
case_images: Switzerland) levels at the fifth injection showed significant rebound (TRAP-5b level: from 124 mU/dl to 1813 mU/dl; total-P1NP level: from 13.6 mug/L to 175 mug/L; Figure 1). Similarly, we noted a substantial decrease in the 2D-BMD, as measured by
case_images: 2D-BMD levels measured by DXA. DXA revealed that there was a significant decrease in bone mineral density after discontinuation of denosumab treatment.. Abbreviations: 2D-BMD, two-dimensional bone mineral density; DXA, dual energy X-ray absorptiometry; Dmab, Denosumab; BMD, bone mineral density; LS, lumbar spine; FN, femoral neck.
case_images: CIA-14-1445-g0002.jpg
case_images: PMC6689764_01_CIA-14-1445-g0002.jpg
case_images: F0002
case_images: FN: from 0.449 g/cm2 to 0.327 g/cm2; Figure 2) [T-score (LS): from -2.1 to -3.1; (FN): from -2.1 to -3.1][Z-score (LS): from 0.1 to -0.6; (FN): from -0.7 to -1.9]. During the 3D-BMD analysis using QCT, a rapid decrease in BMD, including a decrease in the levels of the cortical parameters of the hip, was observed after denosumab discontinuation [LS: form 96.6 g/cm3 to 88.1 g/cm3; total hip (TH): from 594.1 g/cm3 to 566.4 g/cm3; cortical BMD: from 594.3 mg/cm3 to 566.5 mg/cm3; cortical thickness: from 1.146 mm to 0.956 mm; Figures 3 and 4]. Furthermore, measurement of the biomechanical parameters of the hip revealed bone fragility after discontinuation of denosumab [a higher buckling ratio (BR), which is an index of cortical instability (from 19.6 to 23.2) and a lower cross-sectional moment of inertia (CSMI), which is an index of bending (from 1.293 cm4 to 1.278 cm4); Figure 5].
case_images: 3D-BMD levels measured by QCT. QCT revealed that there was a significant decrease in bone mineral density after discontinuation of denosumab treatment.. Abbreviations: 3D-BMD, three-dimensional bone mineral density; QCT, quantitative computed tomography; Dmab, denosumab; BMD, bone mineral density; LS, lumbar spine; TH, total hip.
case_images: CIA-14-1445-g0003.jpg
case_images: PMC6689764_01_CIA-14-1445-g0003.jpg
case_images: F0003
case_images: FN: from 0.449 g/cm2 to 0.327 g/cm2; Figure 2) [T-score (LS): from -2.1 to -3.1; (FN): from -2.1 to -3.1][Z-score (LS): from 0.1 to -0.6; (FN): from -0.7 to -1.9]. During the 3D-BMD analysis using QCT, a rapid decrease in BMD, including a decrease in the levels of the cortical parameters of the hip, was observed after denosumab discontinuation [LS: form 96.6 g/cm3 to 88.1 g/cm3; total hip (TH): from 594.1 g/cm3 to 566.4 g/cm3; cortical BMD: from 594.3 mg/cm3 to 566.5 mg/cm3; cortical thickness: from 1.146 mm to 0.956 mm; Figures 3 and 4]. Furthermore, measurement of the biomechanical parameters of the hip revealed bone fragility after discontinuation of denosumab [a higher buckling ratio (BR), which is an index of cortical instability (from 19.6 to 23.2) and a lower cross-sectional moment of inertia (CSMI), which is an index of bending (from 1.293 cm4 to 1.278 cm4); Figure 5].
case_images: Cortical parameters of the hip measured by QCT. QCT revealed that the cortical parameter (cortical thickness and cortical BMD) decreased after discontinuation of denosumab treatment.. Abbreviations: QCT, quantitative computed tomography; Dmab, Denosumab; C-thickness, cortical thickness; C-BMD, cortical bone mineral density.
case_images: CIA-14-1445-g0004.jpg
case_images: PMC6689764_01_CIA-14-1445-g0004.jpg
case_images: F0004
case_images: FN: from 0.449 g/cm2 to 0.327 g/cm2; Figure 2) [T-score (LS): from -2.1 to -3.1; (FN): from -2.1 to -3.1][Z-score (LS): from 0.1 to -0.6; (FN): from -0.7 to -1.9]. During the 3D-BMD analysis using QCT, a rapid decrease in BMD, including a decrease in the levels of the cortical parameters of the hip, was observed after denosumab discontinuation [LS: form 96.6 g/cm3 to 88.1 g/cm3; total hip (TH): from 594.1 g/cm3 to 566.4 g/cm3; cortical BMD: from 594.3 mg/cm3 to 566.5 mg/cm3; cortical thickness: from 1.146 mm to 0.956 mm; Figures 3 and 4]. Furthermore, measurement of the biomechanical parameters of the hip revealed bone fragility after discontinuation of denosumab [a higher buckling ratio (BR), which is an index of cortical instability (from 19.6 to 23.2) and a lower cross-sectional moment of inertia (CSMI), which is an index of bending (from 1.293 cm4 to 1.278 cm4); Figure 5].
case_images: Biomechanical parameters of the hip measured by QCT. QCT revealed that the BR (index of cortical instability) increased and CSMI (index of bending strength) decreased after discontinuation of denosumab treatment.. Abbreviations: QCT, quantitative computed tomography; Dmab, Denosumab; BR, buckling ratio; CSMI, cross-sectional moment of inertia.
case_images: CIA-14-1445-g0005.jpg
case_images: PMC6689764_01_CIA-14-1445-g0005.jpg
case_images: F0005
case_images: FN: from 0.449 g/cm2 to 0.327 g/cm2; Figure 2) [T-score (LS): from -2.1 to -3.1; (FN): from -2.1 to -3.1][Z-score (LS): from 0.1 to -0.6; (FN): from -0.7 to -1.9]. During the 3D-BMD analysis using QCT, a rapid decrease in BMD, including a decrease in the levels of the cortical parameters of the hip, was observed after denosumab discontinuation [LS: form 96.6 g/cm3 to 88.1 g/cm3; total hip (TH): from 594.1 g/cm3 to 566.4 g/cm3; cortical BMD: from 594.3 mg/cm3 to 566.5 mg/cm3; cortical thickness: from 1.146 mm to 0.956 mm; Figures 3 and 4]. Furthermore, measurement of the biomechanical parameters of the hip revealed bone fragility after discontinuation of denosumab [a higher buckling ratio (BR), which is an index of cortical instability (from 19.6 to 23.2) and a lower cross-sectional moment of inertia (CSMI), which is an index of bending (from 1.293 cm4 to 1.278 cm4); Figure 5].